| Trend | Range | |
|---|---|---|
| Product and professional liability |  |
+0% to +10% |
Key takeaway
We are still experiencing rate stability within the life sciences product/professional liability marketplace, largely due to the ongoing influx of new capacity and no signs of a slowdown in marketplace competition. Rates are largely dependent on individual risk characteristics, with flat to low single-digit rate increases still being attainable for well-performing risks.
- GLP-1 receptor agonists and related medications remain at the forefront, with new indications being approved and older versions beginning to come off patent. Carrier appetite for these types of drugs hinges on an organization’s position in the stream of commerce, with contract manufacturers being on the more attractive end and compounding pharmacies being some of the most challenging. Regardless, insurers are paying close attention to their overall limits exposed to this class of medications.
- With the continued increase in telehealth and connected device risks, a handful of new digital health policy forms are emerging which are expected to provide additional coverage options and create additional competition in this space.
- Social inflation, nuclear verdicts and litigation funding continue to drive both claim costs and the volume of lawsuits.
